MIRA Pharmaceuticals, Inc.
MIRAHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeMIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. Valued at $26.0M, MIRA is a micro-cap name in its sector. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial.
Market Cap
$26.0M
Beta
1.49
P/E (TTM)
—
P/E (Fwd)
-1.51
EPS (TTM)
$-1.14
EPS (Fwd)
$-0.41
ROE
-217.1%
ROA
-129.6%
Cash
$8.1M
Total Debt
$0
Free CF
-$1.0M
52W Change
-58.7%
Annual Financials
Cash vs Debt
Where MIRA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MIRA finished 29.67% below its 150-day moving average ($0.91) and 36.00% below its 200-day moving average ($1.00). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MIRA overbought or oversold?
At the October 20, 2026 close, MIRA's RSI(14) was 20.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
MIRA Pharmaceuticals, Inc. reports $8.1M in cash and $0 in total debt. Free cash flow is running at -$1.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -217.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for MIRA Pharmaceuticals, Inc. and its sector.